Droperidol QT risk management
Risk management and assessment for QTc prolongation associated with the anesthetic/antiemetic droperidol (Akorn's Inapsine and generics) will be discussed by FDA's Anesthetic & Life Support Drugs Advisory Committee on Nov. 18. Several risk management steps were implemented when the safety concern was discovered in December 2001 (1"The Pink Sheet" Dec. 10, 2001, p. 23). The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. [To 2watch a webcast or video of this and other meetings, go to FDAAdvisoryCommittee.com.]....
You may also be interested in...
Updated labeling for Akorn's Inapsine and droperidol generics restricts the drug to second-line use for a narrowed indication due to the risk of fatal cardiac arrhythmias
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.